Edward Reardon, DO
Rheumatology · Warwick, RINPI 1760488449
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $320,626 of the $402,556 with a category attached, or 79.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 21.6%. Reporting peaked in 2019 at $107,655 and has fallen 61.1% since, to $41,866 in 2025. Among rheumatology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,635 payments — averaging $246.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$87K
- Mallinckrodt Hospital Products Inc.$86K
- GSK$51K
- Amgen$47K
- Pfizer$42K
- UCB, Inc.$42K
- plus $47K from 23 others
What the payments were for
- Consulting fees$13,9303%
- Speaking & faculty fees$320,62680%
- Travel & lodging$35,3579%
- Food & beverage$32,5588%
- Education$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 267 | $87,151 |
| Mallinckrodt Hospital Products Inc. | 135 | $86,226 |
| GSK | 116 | $50,750 |
| Amgen(2 entities) | 300 | $46,993 |
| Pfizer | 144 | $42,440 |
| UCB, Inc. | 160 | $42,349 |
| Mallinckrodt Enterprises LLC | 17 | $18,759 |
| Novartis | 77 | $9,567 |
| Regeneron Healthcare Solutions, Inc. | 26 | $8,658 |
| Johnson & Johnson(2 entities) | 216 | $5,564 |
| Lilly USA, LLC | 24 | $673 |
| Sanofi | 4 | $629 |
| Hikma Pharmaceuticals USA | 23 | $389 |
| Genentech USA, Inc. | 23 | $388 |
| E.r. Squibb & Sons, L.L.C. | 19 | $354 |
| AstraZeneca | 16 | $282 |
| Bristol Myers Squibb | 10 | $270 |
| Fresenius Kabi USA, LLC | 12 | $213 |
| ANI Pharmaceuticals, Inc. | 8 | $206 |
| Medexus Pharma, Inc. | 11 | $144 |
| Boehringer Ingelheim | 5 | $126 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Merck | 7 | $98 |
| Organon | 7 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Sobi, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$402,556 in reported general payments places this provider in the 95th percentile of 22 rheumatology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 45 | $370,390 |
| EnbrelEtanercept | 24 | $205,044 |
| Enbrel SureclickEtanercept | 21 | $150,374 |
| OtezlaApremilast | 24 | $110,982 |
| SimponiGolimumab | 12 | $70,071 |
| Xeljanz XrTofacitinib Citrate | 11 | $63,140 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $61,904 |
| SaphneloAnifrolumab-Fnia | 11 | $61,299 |
| OxycontinOxycodone Hcl | 16 | $60,271 |
| OrenciaAbatacept/Maltose | 12 | $34,198 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 622 | $13,307 |
| Hydroxychloroquine Sulfate | 198 | $9,786 |
| MethotrexateMethotrexate Sodium | 288 | $6,534 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 99 | $5,543 |
| Oxycodone Hcl | 135 | $4,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $46,993 | $316,02548 claims |
| Johnson & JohnsonSimponi | $5,564 | $70,07112 claims |
| UCB, Inc.Cimzia (2 Pack) | $42,349 | $61,90411 claims |
| AstraZenecaSaphnelo | $282 | $61,29911 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $354 | $34,19812 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate | $389 | $40325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 rheumatology providers in Rhode Island.
Other rheumatology in Warwick
- Isha ShahWarwick$1K
- Jan KarczewskiWarwick$364
- Jay ToderJohnston$139K
- Deepan DalalCranston$122K
- Anthony ReginatoE. Providence$109K
- David KadmonLincoln$13K
- Christopher D ArcyWesterly$7K
- Jack MouradCranston$4K
- Vinit Joseph GilvazPawtucket$4K
- Wendy SilversmithWesterly$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.